IN2015DN03733A - - Google Patents
Info
- Publication number
- IN2015DN03733A IN2015DN03733A IN3733DEN2015A IN2015DN03733A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A IN 3733DEN2015 A IN3733DEN2015 A IN 3733DEN2015A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A
- Authority
- IN
- India
- Prior art keywords
- scaffold
- ester
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261725949P | 2012-11-13 | 2012-11-13 | |
PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03733A true IN2015DN03733A (no) | 2015-09-18 |
Family
ID=49725346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3733DEN2015 IN2015DN03733A (no) | 2012-11-13 | 2013-11-12 |
Country Status (7)
Country | Link |
---|---|
US (6) | US9765031B2 (no) |
EP (1) | EP2919779B1 (no) |
JP (1) | JP6272626B2 (no) |
CN (1) | CN104884057B (no) |
CA (1) | CA2889697C (no) |
IN (1) | IN2015DN03733A (no) |
WO (1) | WO2014078309A1 (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2015DN03733A (no) * | 2012-11-13 | 2015-09-18 | Us Health | |
US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
US10329259B2 (en) | 2014-05-09 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
US20180273485A1 (en) * | 2015-06-04 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Cannabinoid receptor mediating compounds |
EP3423448A1 (en) * | 2016-03-04 | 2019-01-09 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
AU2021242808A1 (en) * | 2020-03-24 | 2022-10-06 | Novo Nordisk A/S | Solid dispersions of amorphous 3, 4-diphenyl-4, 5-dihydro- 1H-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid CB1 receptor inhibitors |
AU2021253263A1 (en) * | 2020-04-07 | 2022-10-13 | Novo Nordisk A/S | Process for producing 4,5-dihydro-1H-pyrazoles and intermediates |
WO2023159317A1 (en) * | 2022-02-24 | 2023-08-31 | Inversago Pharma Inc. | Methods for treating subjects with abdominal obesity hypertriglyceridemia and/or impaired glucose |
WO2023177568A1 (en) * | 2022-03-14 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor modulating compounds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
DZ3335A1 (fr) | 2000-03-23 | 2001-09-27 | Solvay Pharm Bv | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1 |
ATE284872T1 (de) * | 2001-03-22 | 2005-01-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung |
PL368441A1 (en) * | 2001-09-21 | 2005-03-21 | Solvay Pharmaceuticals B.V. | Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
HUP0402113A3 (en) | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
CN100563651C (zh) | 2004-01-30 | 2009-12-02 | 索尔瓦药物有限公司 | 具有cb1-拮抗活性的1,3,5-三取代的4,5-二氢-1h-吡唑衍生物 |
EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
CA2651385C (en) | 2006-05-05 | 2015-02-03 | John F. Mcelroy | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
KR20100091255A (ko) | 2007-12-10 | 2010-08-18 | 7티엠 파마 에이/에스 | 카나비노이드 수용체 조절자 |
WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
JP5946192B2 (ja) * | 2010-11-18 | 2016-07-05 | ジェンリン ディスカバリーJenrin Discovery | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬/逆作動薬 |
US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
IN2015DN03733A (no) | 2012-11-13 | 2015-09-18 | Us Health | |
US10329259B2 (en) | 2014-05-09 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
US20180273485A1 (en) * | 2015-06-04 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en active Application Filing
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
-
2017
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180022705A1 (en) | 2018-01-25 |
JP2015536997A (ja) | 2015-12-24 |
US10787419B2 (en) | 2020-09-29 |
CN104884057A (zh) | 2015-09-02 |
US20160039766A1 (en) | 2016-02-11 |
US11485709B2 (en) | 2022-11-01 |
CA2889697C (en) | 2023-03-14 |
US11939297B2 (en) | 2024-03-26 |
US20200331861A1 (en) | 2020-10-22 |
CN104884057B (zh) | 2019-08-20 |
WO2014078309A8 (en) | 2015-05-21 |
WO2014078309A1 (en) | 2014-05-22 |
US20230202983A1 (en) | 2023-06-29 |
CA2889697A1 (en) | 2014-05-22 |
US20230219896A1 (en) | 2023-07-13 |
US20180022706A1 (en) | 2018-01-25 |
JP6272626B2 (ja) | 2018-01-31 |
EP2919779A1 (en) | 2015-09-23 |
US9765031B2 (en) | 2017-09-19 |
EP2919779B1 (en) | 2021-01-06 |
US10683270B2 (en) | 2020-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03733A (no) | ||
NO2021034I1 (no) | pemigatinib or a pharmaceutically acceptable salt thereof | |
NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
HK1208801A1 (en) | Orally administered medical composition | |
PL2768479T3 (pl) | Zaróbki do kompozycji terapeutycznych zawierających nikotynę | |
EP2931730A4 (en) | 4-PYRIDINONETRIAZINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
EP3082817A4 (en) | Compositions for drug administration | |
IL231485A0 (en) | Medicinal compounds are immune to interference | |
MY187718A (en) | Pharmaceutical formulations | |
HK1205462A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
HRP20190050T1 (hr) | Farmaceutski pripravci za kombinacijsku terapiju | |
EP2877469A4 (en) | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE | |
HK1206292A1 (en) | Medicament administration | |
HUP1100641A2 (en) | A new diaza-benzofluoranthene derivate as drug | |
DK2420219T3 (da) | Indgivelsesport | |
EP2864328B8 (en) | Pharmaceutically active compounds | |
EP2709593A4 (en) | PHARMACEUTICAL COMPOSITION OF MULTIPLE PARTICLES | |
EP2688566A4 (en) | ANTICANCER THERAPEUTIC AGENTS | |
EP3069311A4 (en) | Delivering a publication to a subscriber | |
IL220512A0 (en) | Compositions for topical administration | |
PT2814473T (pt) | Composições farmacêuticas para terapia de combinação |